Advertisement

Ads Placeholder
Loading...

Artrya Limited

AYA.AXASX
Healthcare
Medical - Healthcare Information Services
$3.13
$-0.14(-4.28%)
Australian Market opens in 3h 58m

Artrya Limited Fundamental Analysis

Artrya Limited (AYA.AX) shows weak financial fundamentals with a PE ratio of -21.12, profit margin of -679.59%, and ROE of -35.63%. The company generates $0.0B in annual revenue with weak year-over-year growth of 0.00%.

Key Strengths

Cash Position18.42%
PEG Ratio-3.80
Current Ratio37.11

Areas of Concern

ROE-35.63%
Operating Margin-757.41%
We analyze AYA.AX's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -50974.9/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-50974.9/100

We analyze AYA.AX's fundamental strength across five key dimensions:

Efficiency Score

Weak

AYA.AX struggles to generate sufficient returns from assets.

ROA > 10%
-21.38%

Valuation Score

Excellent

AYA.AX trades at attractive valuation levels.

PE < 25
-21.12
PEG Ratio < 2
-3.80

Growth Score

Weak

AYA.AX faces weak or negative growth trends.

Revenue Growth > 5%
0.00%
EPS Growth > 10%
0.00%

Financial Health Score

Excellent

AYA.AX maintains a strong and stable balance sheet.

Debt/Equity < 1
0.01
Current Ratio > 1
37.11

Profitability Score

Weak

AYA.AX struggles to sustain strong margins.

ROE > 15%
-3562.61%
Net Margin ≥ 15%
-679.59%
Positive Free Cash Flow
No

Key Financial Metrics

Is AYA.AX Expensive or Cheap?

P/E Ratio

AYA.AX trades at -21.12 times earnings. This suggests potential undervaluation.

-21.12

PEG Ratio

When adjusting for growth, AYA.AX's PEG of -3.80 indicates potential undervaluation.

-3.80

Price to Book

The market values Artrya Limited at 4.66 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

4.66

EV/EBITDA

Enterprise value stands at -19.28 times EBITDA. This is generally considered low.

-19.28

How Well Does AYA.AX Make Money?

Net Profit Margin

For every $100 in sales, Artrya Limited keeps $-679.59 as profit after all expenses.

-679.59%

Operating Margin

Core operations generate -757.41 in profit for every $100 in revenue, before interest and taxes.

-757.41%

ROE

Management delivers $-35.63 in profit for every $100 of shareholder equity.

-35.63%

ROA

Artrya Limited generates $-21.38 in profit for every $100 in assets, demonstrating efficient asset deployment.

-21.38%

Following the Money - Real Cash Generation

Operating Cash Flow

Artrya Limited generates limited operating cash flow of $-19.08M, signaling weaker underlying cash strength.

$-19.08M

Free Cash Flow

Artrya Limited generates weak or negative free cash flow of $-19.35M, restricting financial flexibility.

$-19.35M

FCF Per Share

Each share generates $-0.17 in free cash annually.

$-0.17

FCF Yield

AYA.AX converts -5.68% of its market value into free cash.

-5.68%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-21.12

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-3.80

vs 25 benchmark

P/B Ratio

Price to book value ratio

4.66

vs 25 benchmark

P/S Ratio

Price to sales ratio

12988.90

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.006

vs 25 benchmark

Current Ratio

Current assets to current liabilities

37.11

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.36

vs 25 benchmark

ROA

Return on assets percentage

-0.21

vs 25 benchmark

ROCE

Return on capital employed

-0.24

vs 25 benchmark

How AYA.AX Stacks Against Its Sector Peers

MetricAYA.AX ValueSector AveragePerformance
P/E Ratio-21.1228.31 Better (Cheaper)
ROE-35.63%699.00% Weak
Net Margin-67958.62%-130884.00% (disorted) Weak
Debt/Equity0.010.34 Strong (Low Leverage)
Current Ratio37.112775.16 Strong Liquidity
ROA-21.38%-14469.00% (disorted) Weak

AYA.AX outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Artrya Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

0.00%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-618.95%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-421.69%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ